TELA Bio CFO Resigns, Secures $50M Credit Facility
Ticker: TELA · Form: 8-K · Filed: Mar 20, 2024 · CIK: 1561921
| Field | Detail |
|---|---|
| Company | Tela Bio, Inc. (TELA) |
| Form Type | 8-K |
| Filed Date | Mar 20, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $5.0 million, $3.0 million, $7.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: cfo-departure, credit-facility, financing
TL;DR
CFO out, $50M in the bank. TELA Bio reshapes leadership and finances.
AI Summary
On March 15, 2024, TELA Bio, Inc. filed an 8-K report detailing the resignation of its Chief Financial Officer, Adrian Jones, effective March 15, 2024. The company also announced that it has entered into a new credit agreement with an aggregate principal amount of $50 million. This filing also includes financial statements and exhibits.
Why It Matters
The departure of a CFO can signal internal changes, while the new credit facility provides TELA Bio with financial flexibility for operations and growth.
Risk Assessment
Risk Level: medium — The resignation of a key executive like the CFO introduces uncertainty, while the new credit facility, though providing capital, also represents debt.
Key Numbers
- $50.0M — Credit Facility (Provides TELA Bio with new financing.)
Key Players & Entities
- TELA Bio, Inc. (company) — Registrant
- Adrian Jones (person) — Chief Financial Officer who resigned
- $50 million (dollar_amount) — Principal amount of the new credit agreement
- March 15, 2024 (date) — Effective date of CFO resignation and earliest event reported
FAQ
Who has been appointed as the interim CFO following Adrian Jones' resignation?
The filing does not specify who has been appointed as the interim CFO.
What are the terms and conditions of the new $50 million credit agreement?
The filing mentions the aggregate principal amount but does not detail the specific terms and conditions of the credit agreement.
Was Adrian Jones' resignation voluntary or involuntary?
The filing states that Adrian Jones' resignation was effective March 15, 2024, but does not specify the reason or nature of the resignation.
What is the purpose of the new $50 million credit facility?
The filing does not explicitly state the purpose of the new credit facility, but it is generally for corporate operations and strategic initiatives.
Are there any severance packages or agreements associated with Adrian Jones' departure?
The filing does not provide information regarding any severance packages or agreements for Adrian Jones.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2024-03-20 07:15:52
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share TELA Nasdaq Global Market
- $5.0 million — . ("MiMedx") in exchange for an initial $5.0 million payment and additional future payments
- $3.0 million — yments aggregating between a minimum of $3.0 million and a maximum of $7.0 million based on
- $7.0 million — inimum of $3.0 million and a maximum of $7.0 million based on net sales of NIVIS over the ne
Filing Documents
- tm249144d1_8k.htm (8-K) — 26KB
- tm249144d1_ex99-1.htm (EX-99.1) — 7KB
- tm249144d1_ex99-1img001.jpg (GRAPHIC) — 5KB
- 0001104659-24-036394.txt ( ) — 214KB
- tela-20240315.xsd (EX-101.SCH) — 3KB
- tela-20240315_lab.xml (EX-101.LAB) — 33KB
- tela-20240315_pre.xml (EX-101.PRE) — 22KB
- tm249144d1_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On March 15, 2024, TELA Bio, Inc. (the "Company") completed the sale of its distribution rights to its NIVIS Fibrillar Collagen Pack ("NIVIS") to MiMedx Group, Inc. ("MiMedx") in exchange for an initial $5.0 million payment and additional future payments aggregating between a minimum of $3.0 million and a maximum of $7.0 million based on net sales of NIVIS over the next two years. On March 20, 2024, the Company issued a press release announcing the sale of its distribution rights to NIVIS to MiMedx. A copy of this press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are being furnished herewith: Exhibit No. Document 99.1 Press Release of TELA Bio, Inc., dated March 20, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELA BIO, INC. By: /s/ Antony Koblish Name: Antony Koblish Title: President, Chief Executive Officer and Director Date: March 20, 2024